APA (7th ed.) Citation

Pan, Y., Li, M., Yu, M., Chen, J., Yu, H., Liu, K., & Chen, L. High-dose furmonertinib plus bevacizumab in EGFR-mutant non-small cell lung cancer with brain metastases after resistance to third-generation EGFR-TKIs: A retrospective study. Elsevier.

Chicago Style (17th ed.) Citation

Pan, Yin, Meichen Li, Mingjie Yu, Jing Chen, Hui Yu, Kaijing Liu, and Likun Chen. High-dose Furmonertinib Plus Bevacizumab in EGFR-mutant Non-small Cell Lung Cancer with Brain Metastases After Resistance to Third-generation EGFR-TKIs: A Retrospective Study. Elsevier.

MLA (9th ed.) Citation

Pan, Yin, et al. High-dose Furmonertinib Plus Bevacizumab in EGFR-mutant Non-small Cell Lung Cancer with Brain Metastases After Resistance to Third-generation EGFR-TKIs: A Retrospective Study. Elsevier.